Johnson & Johnson (NYSE: JNJ)
Health Care · Pharmaceuticals · US
$271.16
+0.34% today · +51.0% 1Y
Johnson & Johnson (NYSE: JNJ) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $651.25B and employs 141,700 people.
Over the last twelve months the share price has gained 51.0%, trading between 173.33 and 276.47.
Tweenvest scores Johnson & Johnson across four factors: quality 90/100, value 18/100, growth 52/100, dividend 81/100. Its strongest factor is quality.
JNJ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $651.25B
- Revenue (TTM)
- $97.93B
- P/E
- 31.33
- EPS
- 8.63
- Dividend yield
- 2.00%
- Beta (5Y)
- 0.23
- 52-week high
- $276.47
- 52-week low
- $173.33
- Avg volume (3M)
- —
- Shares outstanding
- 2.41B
- Employees
- 141,700
- Next earnings
- —
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
- ISIN
- US4781601046
- Founded
- 1886
- Listed since
- Jan 2, 1962
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.18 | -0.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.23% |
| Bristol-Myers Squibb CompanyNYSE: BMY | $136.88B | $67.39 | +0.57% |
Figures last refreshed Aug 18, 2026.